Skip to main content
SpringerLink
Log in

Patient Assessment and Diagnosis

  • Chapter
  • First Online:
Managing Diabetic Nephropathies in Clinical Practice

  • 772 Accesses

Abstract

The 2015 International Diabetes Federation Atlas reported that 415 million people live with diabetes worldwide, and 642 million people will have diabetes worldwide by 2040 [1]. Long-term disease results in vascular changes and dysfunction, which are major causes of morbidity and mortality in patients with diabetes. Among diabetic vascular complications, diabetic nephropathy (DN) is a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) [2]. Moderately and severely increased albuminuria and a decline in the glomerular filtration rate (GFR) are early markers of CKD and are recognized as independent risk factors for the development of ESRD and the onset of cardiovascular diseases (CVD). Therefore, the early assessment of DN in patients with diabetes is critical.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. International Diabetes Federation (IDF). IDF diabetes atlas update 2015. www.diabetesatlas.org/resources/2015-atlas.html. Accessed February 2, 2016.

  2. Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, et al. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis. 2012;59:75–83.

    Article  PubMed  Google Scholar 

  3. Kitada M, Zhang Z, Mima A, King GL. Molecular mechanisms of diabetic vascular complications. J Diabetes Investig. 2010;1:77–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93:137–88.

    Article  CAS  PubMed  Google Scholar 

  5. Giunti S, Barit D, Cooper ME. Mechanisms of diabetic nephropathy: role of hypertension. Hypertension. 2006;48:519–26.

    Article  CAS  PubMed  Google Scholar 

  6. Koya D, Araki S-I, Haneda M. Therapeutic management of diabetic kidney disease. J Diabetes Investig. 2011;4:248–54.

    Article  Google Scholar 

  7. Araki S, Haneda M, Koya D, Kashiwagi A, Uzu T, Kikkawa R. Clinical impact of reducing microalbuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2008;Suppl 1:S54–8.

    Article  Google Scholar 

  8. Levey AS, de Jong PE, Coresh J, Nahas MEI, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int. 2011;80:17–28.

    Article  PubMed  Google Scholar 

  9. Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:164–76.

    Article  PubMed  Google Scholar 

  10. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7:35–43.

    Article  PubMed  Google Scholar 

  11. Lane JT. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. Am J Physiol Renal Physiol. 2004;286:F442–50.

    Article  CAS  PubMed  Google Scholar 

  12. Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis. 2006;47:927–46.

    Article  CAS  PubMed  Google Scholar 

  13. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63:225–32.

    Article  PubMed  Google Scholar 

  14. Maatman RG, Van Kuppevelt TH, Veerkamp JH. Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem J. 1991;273:759–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Thomas ME, Schreiner GF. Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin. Am J Nephrol. 1993;13:385–98.

    Article  CAS  PubMed  Google Scholar 

  16. Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hase H, Kaneko T, et al. Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int. 2002;62:1628–37.

    Article  CAS  PubMed  Google Scholar 

  17. Araki S, Haneda M, Koya D, Sugaya T, Isshiki K, Kume S, et al. Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care. 2013;36:1248–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro 3rd AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Najafian B, Mauer M. Progression of diabetic nephropathy in type 1 diabetic patients. Diabetes Res Clin Pract. 2009;83:1–8.

    Article  CAS  PubMed  Google Scholar 

  21. Ziyadeh FN. Significance of tubulointerstitial changes in diabetic renal disease. Kidney Int Suppl. 1996;54:S10–3.

    CAS  PubMed  Google Scholar 

  22. Suzuki D, Miyazaki M, Jinde K, Koji T, Yagame M, Endoh M, et al. In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy. Kidney Int. 1997;52:111–21.

    Article  CAS  PubMed  Google Scholar 

  23. Kado S, Aoki A, Wada S, Katayama Y, Kugai N, Yoshizawa N, et al. Urinary type IV collagen as a marker for early diabetic nephropathy. Diabetes Res Clin Pract. 1996;31:103–8.

    Article  CAS  PubMed  Google Scholar 

  24. Yagame M, Suzuki D, Jinde K, Saotome N, Sato H, Noguchi M, et al. Significance of urinary type IV collagen in patients with diabetic nephropathy using a highly sensitive one-step sandwich enzyme immunoassay. J Clin Lab Anal. 1997;11:110–6.

    Article  CAS  PubMed  Google Scholar 

  25. Kotajima N, Kimura T, Kanda T, Obata K, Kuwabara A, Fukumura Y, et al. Type IV collagen as an early marker for diabetic nephropathy in non-insulin-dependent diabetes mellitus. J Diabetes Complications. 2000;14:13–7.

    Article  CAS  PubMed  Google Scholar 

  26. Watanabe H, Sanada H, Shigetomi S, Katoh T, Watanabe T. Urinary excretion of type IV collagen as a specific indicator of the progression of diabetic nephropathy. Nephron. 2000;86:27–35.

    Article  CAS  PubMed  Google Scholar 

  27. Cohen MP, Lautenslager GT, Shearman CW. Increased collagen IV excretion in diabetes. A marker of compromised filtration function. Diabetes Care. 2001;24:914–8.

    Article  CAS  PubMed  Google Scholar 

  28. Tomino Y, Suzuki S, Azushima C, Shou I, Iijima T, Yagame M, et al. Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. J Clin Lab Anal. 2001;15:188–92.

    Article  CAS  PubMed  Google Scholar 

  29. Araki S, Haneda M, Koya D, Isshiki K, Kume S, Sugimoto T, et al. Association between urinary type IV collagen level and deterioration of renal function in type 2 diabetic patients without overt proteinuria. Diabetes Care. 2010;33:1805–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Navarro-González J, Mora-Fernández C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19:433–42.

    Article  PubMed  Google Scholar 

  31. Flyvbjerg A. Diabetic angiopathy, the complement system and the tumor necrosis factor superfamily. Nat Rev Endocrinol. 2010;6:94–101.

    Article  CAS  PubMed  Google Scholar 

  32. Zoppini G, Faccini G, Muggeo M, Zenari L, Falezza G, Targher G. Elevated plasma levels of soluble receptors of TNF-alpha and their association with smoking and microvascular complications in young adults with type 1 diabetes. J Clin Endocrinol Metab. 2001;86:3805–8.

    CAS  PubMed  Google Scholar 

  33. Halwachs G, Tiran A, Reisinger EC, Zach R, Sabin K, Fölsch B, et al. Serum levels of the soluble receptor for tumor necrosis factor in patients with renal disease. Clin Investig. 1994;72:473–6.

    Article  CAS  PubMed  Google Scholar 

  34. Pavkov ME, Nelson RG, Knowler WC, Cheng Y, Krolewski AS, Niewczas MA. Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int. 2015;87:812–9.

    Article  CAS  PubMed  Google Scholar 

  35. Pavkov ME, Weil EJ, Fufaa GD, Nelson RG, Lemley KV, Knowler WC, et al. Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney Int. 2016;89:226–34.

    Google Scholar 

  36. Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, et al. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol. 2012;23:516–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015;38:954–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kanazawa Medical University, Uchinada, Japan

    Daisuke Koya

Authors
  1. Daisuke Koya
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Koya, D. (2017). Patient Assessment and Diagnosis. In: Managing Diabetic Nephropathies in Clinical Practice. Adis, Cham. https://doi.org/10.1007/978-3-319-08873-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08873-0_3

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-08872-3

  • Online ISBN: 978-3-319-08873-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation